| Product Code: ETC7349554 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Vasudha | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 Greece Gastrointestinal Diseases Drug Development Market Overview |
3.1 Greece Country Macro Economic Indicators |
3.2 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, 2021 & 2031F |
3.3 Greece Gastrointestinal Diseases Drug Development Market - Industry Life Cycle |
3.4 Greece Gastrointestinal Diseases Drug Development Market - Porter's Five Forces |
3.5 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Disease Type, 2021 & 2031F |
3.6 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Molecular Targets, 2021 & 2031F |
3.7 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Marketed Drugs, 2021 & 2031F |
3.8 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Clinical Trials, 2021 & 2031F |
3.9 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By Route of Administration, 2021 & 2031F |
3.10 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume Share, By End-Users, 2021 & 2031F |
4 Greece Gastrointestinal Diseases Drug Development Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of gastrointestinal diseases in Greece |
4.2.2 Growing awareness and emphasis on healthcare and wellness |
4.2.3 Advancements in medical research and technology in the field of gastroenterology |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for drug approval |
4.3.2 High costs associated with drug development and clinical trials |
4.3.3 Limited availability of skilled professionals and researchers in the field of gastrointestinal diseases |
5 Greece Gastrointestinal Diseases Drug Development Market Trends |
6 Greece Gastrointestinal Diseases Drug Development Market, By Types |
6.1 Greece Gastrointestinal Diseases Drug Development Market, By Disease Type |
6.1.1 Overview and Analysis |
6.1.2 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Disease Type, 2021- 2031F |
6.1.3 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Gastroenteritis, 2021- 2031F |
6.1.4 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Inflammatory Bowel Disease (IBD), 2021- 2031F |
6.1.5 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Irritable Bowel Syndrome, 2021- 2031F |
6.1.6 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.2 Greece Gastrointestinal Diseases Drug Development Market, By Molecular Targets |
6.2.1 Overview and Analysis |
6.2.2 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sodium Transporter NHE3 Inhibitor, 2021- 2031F |
6.2.3 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Sphinogosine-1-Phosphate Receptor Functional Antagonist, 2021- 2031F |
6.2.4 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Tumor Necrosis Factor (TNF) Blocker, 2021- 2031F |
6.2.5 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.3 Greece Gastrointestinal Diseases Drug Development Market, By Marketed Drugs |
6.3.1 Overview and Analysis |
6.3.2 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Infliximab, 2021- 2031F |
6.3.3 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Adalimumab, 2021- 2031F |
6.3.4 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Mesalazine, 2021- 2031F |
6.3.5 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.4 Greece Gastrointestinal Diseases Drug Development Market, By Clinical Trials |
6.4.1 Overview and Analysis |
6.4.2 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Etrolizumab, 2021- 2031F |
6.4.3 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By SHP647, 2021- 2031F |
6.4.4 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ABX464, 2021- 2031F |
6.4.5 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By ASP3291, 2021- 2031F |
6.4.6 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Others, 2021- 2031F |
6.5 Greece Gastrointestinal Diseases Drug Development Market, By Route of Administration |
6.5.1 Overview and Analysis |
6.5.2 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Oral, 2021- 2031F |
6.5.3 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Injectable, 2021- 2031F |
6.6 Greece Gastrointestinal Diseases Drug Development Market, By End-Users |
6.6.1 Overview and Analysis |
6.6.2 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.6.3 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Homecare, 2021- 2031F |
6.6.4 Greece Gastrointestinal Diseases Drug Development Market Revenues & Volume, By Specialty Clinics, 2021- 2031F |
7 Greece Gastrointestinal Diseases Drug Development Market Import-Export Trade Statistics |
7.1 Greece Gastrointestinal Diseases Drug Development Market Export to Major Countries |
7.2 Greece Gastrointestinal Diseases Drug Development Market Imports from Major Countries |
8 Greece Gastrointestinal Diseases Drug Development Market Key Performance Indicators |
8.1 Number of clinical trials initiated for gastrointestinal drugs in Greece |
8.2 Rate of adoption of innovative treatment approaches in the market |
8.3 Investment in research and development for gastrointestinal drug development in Greece |
9 Greece Gastrointestinal Diseases Drug Development Market - Opportunity Assessment |
9.1 Greece Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Disease Type, 2021 & 2031F |
9.2 Greece Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Molecular Targets, 2021 & 2031F |
9.3 Greece Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Marketed Drugs, 2021 & 2031F |
9.4 Greece Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Clinical Trials, 2021 & 2031F |
9.5 Greece Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By Route of Administration, 2021 & 2031F |
9.6 Greece Gastrointestinal Diseases Drug Development Market Opportunity Assessment, By End-Users, 2021 & 2031F |
10 Greece Gastrointestinal Diseases Drug Development Market - Competitive Landscape |
10.1 Greece Gastrointestinal Diseases Drug Development Market Revenue Share, By Companies, 2024 |
10.2 Greece Gastrointestinal Diseases Drug Development Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here